AEP-IN-3 (compound 18) is an orally administered, potent asparagine endopeptidase (AEP) inhibitor that effectively crosses the blood-brain barrier. It boasts an IC50 of 7.8 ± 0.9 nM and is applicable in Alzheimer’s Disease (AD) research [1].

AEP-IN-3（化合物18）具有83%的生物利用度，半衰期为T 1/2 [1]。在具有FVB/N遗传背景的P301L突变的人源Tau 2N4R异构体转基因小鼠中（3.8月龄）[1]，AEP-IN-3（口服，20 mg/kg，每日两次，间隔7-8小时服用，连续5天）显示出在小鼠大脑中显著抑制AEP活性，并减少Tau N368片段的形成，但对总Tau的影响不显著[1]。